Potential amelioration of liver function by low-dose tolvaptan in heart failure patients
Low-dose tolvaptan did not cause liver injury. Pharmacokinetics of tolvaptan may be associated with potential amelioration of liver function in heart failure patients.
Authors
- Emi Nakatsugawa
- Yasuaki Mino (ORCID: https://orcid.org/0000-0002-5706-1117)
- Kohei Hoshikawa
- Yumi Imoto
- Shunta Akutsu
- Masao Saotome
- Yuichiro Maekawa (ORCID: https://orcid.org/0000-0002-6792-8458)
- Takafumi Naito (ORCID: https://orcid.org/0000-0002-7447-3789)
- Junichi Kawakami
Institutions
- Hamamatsu University (JP)
- Hamamatsu University School of Medicine (JP)
- Hamamatsu University Hospital (JP)
- Shinshu University Hospital (JP)
Publication Details
- Journal
- Toxicology Reports
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1016/j.toxrep.2025.102009
- Primary Topic
- Electrolyte and hormonal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00